Page 2 - Biofoundry Services News Today

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it compare to its competitors? We will compare Codex DNA to related companies based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership. Institutional & Insider Ownership 87.6% of […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) and Codex DNA (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Profitability This table compares Nautilus Biotechnology and Codex DNA’s […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Codex DNA to similar companies based on the strength of its valuation, analyst recommendations, profitability, risk, institutional ownership, dividends and earnings. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. Codex DNA Inc. […]

Cue Health (NASDAQ:HLTH – Get Rating) and Codex DNA (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends. Profitability This table compares Cue Health and Codex DNA’s […]

Codex DNA (NASDAQ:DNAY – Get Rating) and Cue Health (NASDAQ:HLTH – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 87.6% of Codex DNA shares […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Codex DNA to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings. Profitability This table compares […]

Codex DNA, Inc. (NASDAQ:DNAY – Get Rating) – Jefferies Financial Group upped their FY2022 earnings estimates for Codex DNA in a note issued to investors on Wednesday, May 11th. Jefferies Financial Group analyst B. Couillard now anticipates that the company will post earnings of ($2.10) per share for the year, up from their prior forecast […]

Codex DNA (NASDAQ:DNAY – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05, MarketWatch Earnings reports. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%. Shares of NASDAQ:DNAY traded up $0.11 […]

Codex DNA (NASDAQ:DNAY – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. […]